Evidence map›Paper›PMID 35057034›Full record

ArticlePharmaceutics2022

Impact of circ-0000221 in the Pathogenesis of Hepatocellular via Modulation of miR-661-PTPN11 mRNA Axis.

Marwa Matboli, Mohmed Kamal Hassan, Mahmoud A Ali, Mohamed Tarek Mansour, Waheba Elsayed, Reham Atteya, Hebatallah Said Aly, Mahmoud El Meteini, Hesham Elghazaly, Sherif El-Khamisy and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Role of Circular RNAs in Liver Diseases.International journal of medical sciences · 2026
    Review
  2. Article
  3. Article
  4. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Marwa MatboliMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo 11381, Egypt.ORCID 0000-0002-6852-3954
Mohmed Kamal HassanCenter for Genomics, Helmy Institute for Medical Sciences, Zewail City for Science and Technology, Giza 12578, Egypt.
Mahmoud A AliDepartment of Biomedical Research, Armed Forces College of Medicine (AFCM), Cairo 11774, Egypt.
Mohamed Tarek MansourDepartment of Biomedical Research, Armed Forces College of Medicine (AFCM), Cairo 11774, Egypt.
Waheba ElsayedCenter for Genomics, Helmy Institute for Medical Sciences, Zewail City for Science and Technology, Giza 12578, Egypt.ORCID 0000-0002-4306-3023
Reham AtteyaCenter for Genomics, Helmy Institute for Medical Sciences, Zewail City for Science and Technology, Giza 12578, Egypt.
Hebatallah Said AlyMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo 11381, Egypt.
Mahmoud El MeteiniDepartment of General Surgery, The School of Medicine, University of Ain Shams, Abbassia, Cairo 11382, Egypt.
Hesham ElghazalyOncology Department, Faculty of Medicine, Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo 11382, Egypt.
Sherif El-KhamisyThe Healthy Lifespan Institute, The Institute of Neuroscience, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, UK.ORCID 0000-0003-2721-7763
Sara H A AgwaClinical pathology and Molecular Genomics Unit, Faculty of Medicine, Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo 11382, Egypt.ORCID 0000-0002-2382-0189
Ain Shams University · EGZewail City of Science and Technology · EGArmed Forces College of Medicine · EGUniversity of Sheffield · GB

Funding

Science and Technology Development Fund BARG call 7, Project ID: 38135
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in Egypt. A deep understanding of the molecular events occurring in HCC can facilitate the development of novel diagnostic and/or therapeutic approaches. In the present study, we describe a novel axis of

Indexed as

hepatocellular carcinomahsa-circ-0000221miR-661PTPN11

Identifiers

PMID35057034
PMCPMC8778063
OpenAlexW4205487430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.